Key points are not available for this paper at this time.
Introduction: Androgenic alopecia, a form of hair loss driven by genetic predisposition and hormonal influences, is the most common cause of hair thinning and baldness in both men and women. Objectives: The main objective of the study is to find the efficacy and therapeutic potential of mesenchymal stem cell–derived exosomes for the treatment of androgenic alopecia. Methodology of the study: This Randomized control trial was conducted at different aesthetics clinics and patients provide the data during 2023 to June 2024. A total of 85 patients, aged between 18 and 55 years, with clinically diagnosed androgenic alopecia (Norwood-Hamilton classification II–V for men, and Ludwig classification I–II for women) were enrolled. Participants with stable hair loss patterns for at least one year and had not undergone any hair loss treatments (such as minoxidil or finasteride) in the six months were included in the study. Results: The treatment group showed a significant increase in hair density, with a mean increase of 35 hairs/cm² over 12 weeks, compared to their baseline density of 100 hairs/cm². This change is statistically significant, as indicated by a p-value of 0.001. In contrast, the placebo group exhibited a negligible increase in hair density, with a mean increase of just 3 hairs/cm², suggesting the effectiveness of the treatment over the placebo. Conclusion: It is concluded that mesenchymal stem cell-derived exosomes significantly enhance hair density and thickness in patients with androgenic alopecia, offering a promising and well-tolerated treatment option.
Dr Hafsa Nadeem (Thu,) studied this question.